Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care

Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview
Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, and transportation issues have all limited access to these advancements in rural and underserved communities. Oncology teams in these settings are also challenged to stay up to date on rapidly evolving clinical evidence and guidance, further contributing to disparities in cancer care. In this activity, expert faculty will review available therapies for metastatic RCC as well as current guideline recommendations and clinical evidence for individualizing treatment in the first- and subsequent-line settings. Evidence-based strategies to identify and overcome barriers to RCC management in rural and underserved areas will also be discussed.

This enduring activity is a recorded session from Oncology Congress that took place on April 1, 2023.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Evaluate available therapies for metastatic RCC based on their efficacy and safety profiles
Apply the latest guidelines and clinical evidence into the development of treatment plans for patients with metastatic RCC in the first- and subsequent-line settings
Implement evidence-based strategies for reducing disparities in RCC care in rural and underserved communities